公开(公告)号：US5116871A

公开(公告)日：1992-05-26

申请号：US397789

申请日：1989-08-24

Applicant: David F. Horrobin ,  John C. M. Stewart

Inventor： David F. Horrobin ,  John C. M. Stewart

IPC: A61K31/20 ,  A61K38/21 ,  A61P9/00 ,  A61P25/00 ,  A61P25/04 ,  A61P29/00 ,  A61P31/12 ,  A61P43/00

CPC classification number: A61K31/20 ,  A61K38/21

Abstract: The use of one or more of the 6-desaturated or higher EFAs of each of the n-6 and n-3 series for the manufacture of a medicament for use in the treatment of post-viral fatigue syndrome (otherwise known as myalgic encephalomyelitis (ME)).

公开(公告)号：US5116624A

公开(公告)日：1992-05-26

申请号：US638998

申请日：1991-01-09

Applicant: David F. Horrobin ,  Frank Corrigan

Inventor： David F. Horrobin ,  Frank Corrigan

IPC: A61K31/20 ,  A61K31/202 ,  A61K31/315 ,  A61K33/04 ,  A61K33/30 ,  A61K35/60 ,  A61K36/00 ,  A61K36/18 ,  A61P25/24 ,  A61P25/26 ,  A61P25/28

CPC classification number: A61K33/04 ,  A61K31/315 ,  A61K33/30 ,  A61K35/60 ,  A61K36/06

Abstract: A pharmaceutical composition of GLA or DGLA and bioavailable selenium, optionally also with an 18:4 or higher n-3 EFA and/or bioavailable zinc.

公开(公告)号：US4886670A

公开(公告)日：1989-12-12

申请号：US159128

申请日：1988-02-23

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/19 ,  A61K31/505 ,  A61K33/14 ,  A61K38/21

CPC classification number: A61K31/70 ,  A61K31/19 ,  A61K31/505 ,  A61K33/14 ,  A61K38/21

Abstract: The anti-viral effectiveness of conventional anti-viral agents such as acylovir, idoxuridine, vidarabine etc. is enhanced by formulation or administration with a physiologically acceptable lithium salt.

Abstract translation: 常规抗病毒剂如acylovir，idoxuridine，阿糖腺苷等的抗病毒效能通过与生理上可接受的锂盐的配制或施用来增强。

公开(公告)号：USRE31836E

公开(公告)日：1985-02-19

申请号：US581671

申请日：1984-02-16

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/23 ,  A61K31/375 ,  A61K31/43 ,  A61K31/485 ,  A61K33/30 ,  A61K45/06

CPC classification number: A61K33/30 ,  A61K31/20 ,  A61K31/23 ,  A61K31/375 ,  A61K31/43 ,  A61K31/485 ,  A61K45/06

Abstract: Composition and use of .gamma.-linolenic acid and related materails with ascorbic acid, or ethyl alcohol, or an opiate antagonist such as naloxone, nalorphine or levallorphan, for treating alcoholism or moderating the effects of taking alcohol.

公开(公告)号：US4444755A

公开(公告)日：1984-04-24

申请号：US272081

申请日：1981-06-10

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/43 ,  A61K31/545 ,  A61K33/30 ,  A61K31/20 ,  A61K31/315 ,  A61K31/54

CPC classification number: A61K33/30 ,  A61K31/43 ,  A61K31/545

Abstract: Use of .gamma.-linolenic acid and related materials alone or with zinc or .beta.-lactam antibiotics to treat skin disorders.

Abstract translation: 单独或与锌或β-内酰胺抗生素一起使用γ-亚麻酸及相关物质治疗皮肤病。

公开(公告)号：US4309415A

公开(公告)日：1982-01-05

申请号：US29058

申请日：1979-04-11

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A23L1/29 ,  A23L1/30 ,  A61K31/20 ,  A61K31/202 ,  A61K31/23 ,  A61K31/34 ,  A61K31/40 ,  A61K31/425 ,  A61K31/43 ,  A61K31/475 ,  A61K31/557 ,  A61K33/30 ,  A61K38/00 ,  A61K38/21 ,  A61K45/06 ,  A61P13/02 ,  A61P15/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  A61K45/02 ,  A61K31/54

CPC classification number: A61K38/21 ,  A61K31/20 ,  A61K31/23 ,  A61K31/34 ,  A61K31/40 ,  A61K31/425 ,  A61K31/43 ,  A61K31/475 ,  A61K31/557 ,  A61K33/30 ,  A61K45/06

Abstract: Compositions and use of .gamma.-linolenic acid and related materials with (i) zinc, .beta.-lactam antibiotics or other materials enhancing physiological 1-series PG synthesis and/or (ii) colchicine, Vinca alkaloids or other materials enhancing physiological synthesis of thromboxane A2, for treatment of inflammatory disorders.

Abstract translation: γ-亚麻酸及相关材料与（i）锌，β-内酰胺抗生素或其他增强生理性1系PG合成的物质和/或（ii）秋水仙碱，长春花生物碱或其他增强凝血恶烷A2生理合成的物质的组合和用途 ，用于治疗炎症性疾病。

公开(公告)号：US4287202A

公开(公告)日：1981-09-01

申请号：US38938

申请日：1979-05-14

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/405 ,  A61K31/47

CPC classification number: A61K31/405 ,  A61K31/47

Abstract: A method for the treatment or prophylaxis of angina pectoris or myocardial infarction which consists of administering indomethacin or chloroquine. It has been found that angina pectoris and myocardial infarction may be susceptible to treatment by administration of substances which will inhibit the synthesis or action of prostaglandins, which it is believed to be the effect of administering indomethacin or chloroquine.

Abstract translation: 治疗或预防心绞痛或心肌梗死的方法，其包括给予吲哚美辛或氯喹。 已经发现，心绞痛和心肌梗塞可能通过施用将抑制前列腺素合成或作用的物质来治疗，这被认为是施用吲哚美辛或氯喹的作用。

公开(公告)号：US06184251B2

公开(公告)日：2001-02-06

申请号：US09254074

申请日：2000-02-04

Applicant: Barbara Jacqueline Stordy ,  David F. Horrobin

Inventor： Barbara Jacqueline Stordy ,  David F. Horrobin

IPC: A61K3120

CPC classification number: A61K31/202

Abstract: This invention relates to the administration of arachidonic acid or docosahexaenoic acid or precursors thereof to children or pregnant women for the treatment or prevention of dyspraxia.

Abstract translation: 本发明涉及向儿童或孕妇施用花生四烯酸或二十二碳六烯酸或其前体用于治疗或预防dyspraxia。

公开(公告)号：US5847000A

公开(公告)日：1998-12-08

申请号：US828716

申请日：1997-03-28

Applicant: David F. Horrobin ,  Philip Knowles ,  Mehar S Manku

Inventor： David F. Horrobin ,  Philip Knowles ,  Mehar S Manku

IPC: A23L1/30 ,  A23L1/302 ,  A61K8/04 ,  A61K8/67 ,  A61K31/375 ,  A61P3/06 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/08 ,  A61P17/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  A61Q19/00 ,  C07D307/62 ,  A61K9/20 ,  A61K9/48

CPC classification number: C07D307/62 ,  A23L33/12 ,  A23L33/15 ,  A61K31/375 ,  A61K8/676 ,  A61Q19/00 ,  A23V2002/00

Abstract: Ascorbyl-GLA or Ascorbyl-DGLA in medicaments for treatment of asthma and other disorders.

Abstract translation: 抗坏血酸基GLA或抗坏血酸基-DGLA用于治疗哮喘和其他疾病的药物。

公开(公告)号：US5589509A

公开(公告)日：1996-12-31

申请号：US611525

申请日：1996-03-06

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/40 ,  A61K31/42 ,  A61K31/65 ,  A61K47/00 ,  A61P9/10 ,  A61P31/12 ,  A61P35/00

CPC classification number: A61K31/20 ,  A61K31/40 ,  A61K31/65 ,  Y10S514/886

Abstract: A composition comprises a polyunsaturated fatty acid, in particular an essential fatty acid of the n-6 series (linoleic acid or its metabolites) or the n-3 series (alpha-linolenic acid and its metabolites), together with a drug that taken alone has a side-effect of sensitizing the skin to light, in particular a porphyrin or tetracycline or Benoxaprofen, alone or in a pharmaceutically acceptable diluent or carrier, the composition reducing that sensitization.

Abstract translation: 组合物包含多不饱和脂肪酸，特别是n-6系列（亚油酸或其代谢物）或n-3系（α-亚麻酸及其代谢物）的必需脂肪酸，以及单独使用的药物 具有使皮肤光敏的副作用，特别是卟啉或四环素或Benoxaprofen，单独或药学上可接受的稀释剂或载体，该组合物降低了该致敏性。